Thierry Gendre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thierry Gendre has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Alain Créange
Department of Neurology, APHP, Hôpital Henri Mondor, Créteil, France
3 shared publications - Benjamin Bardel
UR 4391, Equipe Excitabilité Nerveuse and Thérapeutique (ENT), Faculté de Santé, Université Paris Est Créteil, Créteil, France; Assistance Publique - Hôpitaux de Paris, Hôpital Henri Mondor, Unité de Neurophysiologie Clinique, Créteil, France
3 shared publications Jean‐Pascal Lefaucheur
Faculty of Health, UR 4391 (ENT Team) Paris Est Creteil University (UPEC) Creteil France
3 shared publicationsRomain Gounot
Lymphoid Malignancies Unit, Henri Mondor University Hospital - AP-HP, Créteil, France
3 shared publications- Violaine Planté-Bordeneuve
Department of Neurology, Henri Mondor University Hospital, APHP, Créteil, France
3 shared publications Alain Créange
Faculty of Health, UR 4391, ENT Team Paris Est Creteil University Créteil France
2 shared publications
Latest Publications
- 30 September 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (4) , e70175
Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study
Background and Aims: In anti‐myelin‐associated glycoprotein (MAG) neuropathy, the efficacy of rituximab (RTX) is not demonstrated in randomized controlled trials. Combinations of RTX with conventional chemotherapy (immunochemotherapy, ICT) may provide potential benefit, but systematic evaluations are lacking. We aimed to compare the efficacy and safety of RTX and ICT in a multicenter retrospective real‐world cohort. Methods: Patients with anti‐MAG antibody titers > 10 000 Buhlmann titer units (BTUs) were included. Treatment response was defined as an improvement of ≥ 1 point in the Overall Neuropathy Limitation Scale (ONLS) compared to baseline. Propensity score matching was used to account for differences in baseline characteristics between treatment groups. Results: A total of 230 patients were included: 150 received RTX and 80 received ICT. Mean follow‐up was 4 years (range, 1–20 years). One year after treatment, clinical improvement occurred in 61/147 (41%) patients treated with RTX and 39/78 (50%) treated with ICT (OR = 1.4 [0.8–2.5] p = 0.3). At last follow‐up, clinical improvement occurred in 55/150 (37%) patients treated with RTX and 31/80 (39%) treated with ICT (OR = 1.1 [0.6–1.9] p = 0.8). Propensity score matching yielded similar results. Among ICT regimens, dexamethasone–RTX–cyclophosphamide was associated with the highest response rate. RTX induction, 1 g days 1 and 15, seemed superior to four‐weekly infusions. Adverse events were more frequent with ICT than with RTX (28% vs. 15%; OR = 2.20 [1.07–4.54], p = 0.02). Interpretation: In this cohort, adding chemotherapy to RTX was not associated with greater long‐term improvement, despite a higher rate of adverse events. Prospective controlled studies are needed.
- 30 September 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (4) , e70175
Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study
Background and Aims: In anti‐myelin‐associated glycoprotein (MAG) neuropathy, the efficacy of rituximab (RTX) is not demonstrated in randomized controlled trials. Combinations of RTX with conventional chemotherapy (immunochemotherapy, ICT) may provide potential benefit, but systematic evaluations are lacking. We aimed to compare the efficacy and safety of RTX and ICT in a multicenter retrospective real‐world cohort. Methods: Patients with anti‐MAG antibody titers > 10 000 Buhlmann titer units (BTUs) were included. Treatment response was defined as an improvement of ≥ 1 point in the Overall Neuropathy Limitation Scale (ONLS) compared to baseline. Propensity score matching was used to account for differences in baseline characteristics between treatment groups. Results: A total of 230 patients were included: 150 received RTX and 80 received ICT. Mean follow‐up was 4 years (range, 1–20 years). One year after treatment, clinical improvement occurred in 61/147 (41%) patients treated with RTX and 39/78 (50%) treated with ICT (OR = 1.4 [0.8–2.5] p = 0.3). At last follow‐up, clinical improvement occurred in 55/150 (37%) patients treated with RTX and 31/80 (39%) treated with ICT (OR = 1.1 [0.6–1.9] p = 0.8). Propensity score matching yielded similar results. Among ICT regimens, dexamethasone–RTX–cyclophosphamide was associated with the highest response rate. RTX induction, 1 g days 1 and 15, seemed superior to four‐weekly infusions. Adverse events were more frequent with ICT than with RTX (28% vs. 15%; OR = 2.20 [1.07–4.54], p = 0.02). Interpretation: In this cohort, adding chemotherapy to RTX was not associated with greater long‐term improvement, despite a higher rate of adverse events. Prospective controlled studies are needed.
- Open Access
- 15 September 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (9) , e70363
Relieving Chronic Neuropathic Pain With EEG‐Neurofeedback
Background: Electroencephalography (EEG)‐guided neurofeedback (NFB) is a rarely evaluated neuromodulation technique for the treatment of chronic neuropathic pain.Methods: The analgesic efficacy of EEG‐NFB based on two different EEG targets was assessed in two groups of 16 patients with peripheral neuropathic pain. Twelve EEG‐NFB sessions were performed over 4 weeks to improve the β1/β2 or α/θ ratio in the EEG signal of the central cortical region contralateral to the pain side. Before and 1 week after treatment, pain interference with daily life (primary endpoint), pain intensity, neuropathic symptom profile, pain catastrophizing, anxiety, depression, fatigue, and sleep quality were evaluated. In addition, EEG was recorded in the resting state before and after EEG‐NFB sessions, as well as during the sessions.Results: Significant analgesic effects were observed on the primary endpoint in both groups. However, β1/β2 training specifically reduced the intensity of ongoing and evoked pain, while anxiety and depression were reduced after α/θ training. Responders to β1/β2 training increased β1 activities or β1/β2 ratio in the resting state or during the EEG‐NFB sessions, while an increase in the β1/β2 ratio was also observed during the sessions in responders to α/θ training. In 12 of the 15 responders, a transfer task was performed and showed partial maintenance of therapeutic benefit.Conclusions: EEG‐NFB can produce analgesia with different clinical and neurophysiological impacts according to various EEG targets. These results open perspectives for the use of EEG‐NFB protocols in the treatment of chronic neuropathic pain, based on well‐defined EEG targets.
- 15 September 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (9) , e70363
Open AccessRelieving Chronic Neuropathic Pain With EEG‐Neurofeedback
Background: Electroencephalography (EEG)‐guided neurofeedback (NFB) is a rarely evaluated neuromodulation technique for the treatment of chronic neuropathic pain.Methods: The analgesic efficacy of EEG‐NFB based on two different EEG targets was assessed in two groups of 16 patients with peripheral neuropathic pain. Twelve EEG‐NFB sessions were performed over 4 weeks to improve the β1/β2 or α/θ ratio in the EEG signal of the central cortical region contralateral to the pain side. Before and 1 week after treatment, pain interference with daily life (primary endpoint), pain intensity, neuropathic symptom profile, pain catastrophizing, anxiety, depression, fatigue, and sleep quality were evaluated. In addition, EEG was recorded in the resting state before and after EEG‐NFB sessions, as well as during the sessions.Results: Significant analgesic effects were observed on the primary endpoint in both groups. However, β1/β2 training specifically reduced the intensity of ongoing and evoked pain, while anxiety and depression were reduced after α/θ training. Responders to β1/β2 training increased β1 activities or β1/β2 ratio in the resting state or during the EEG‐NFB sessions, while an increase in the β1/β2 ratio was also observed during the sessions in responders to α/θ training. In 12 of the 15 responders, a transfer task was performed and showed partial maintenance of therapeutic benefit.Conclusions: EEG‐NFB can produce analgesia with different clinical and neurophysiological impacts according to various EEG targets. These results open perspectives for the use of EEG‐NFB protocols in the treatment of chronic neuropathic pain, based on well‐defined EEG targets.
- Open Access
- 20 July 2025
- Published by Taylor & Francis in Amyloid
- Vol. 32 (4) , 364-366
A case of acute myelopathy in ATTR-Val30Met amyloidosis with leptomeningeal involvement: pathophysiological insights and upcoming therapeutic challenges
- 20 July 2025
- Published by Taylor & Francis in Amyloid
- Vol. 32 (4) , 364-366
Open AccessA case of acute myelopathy in ATTR-Val30Met amyloidosis with leptomeningeal involvement: pathophysiological insights and upcoming therapeutic challenges
- Open Access
- 4 April 2025
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 16 (4) , 102236
Short-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study
- 4 April 2025
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 16 (4) , 102236
Open AccessShort-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study
- Open Access
- 19 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70087
Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy
Background: Neuropathies associated with IgA monoclonal gammopathy are poorly understood, and the interpretation of the presence of such gammopathy in a patient with neuropathy may be challenging.Methods: The neurological and hematological features of all patients newly diagnosed with IgA gammopathy by immunofixation in our center from January 2016 to December 2020 were retrospectively analyzed. Patients with neuropathy were identified through the medical records. The etiology was reviewed by two neurologists and classified into three groups: (i) IgA‐related neuropathies, (ii) IgA‐unrelated neuropathies with an identified alternative etiology, and (iii) neuropathies of uncertain relationship with IgA (NURIA) based on a negative extensive work‐up.Results: Among 585 patients with IgA gammopathy, 79 had neuropathy (14%). Neuropathy was IgA‐related in 10 patients (13%): eight AL amyloidosis and two POEMS. In this group, the core features were neuropathic pain, autonomic dysfunction, fatigue or weight loss, and a lambda light chain. IgA‐unrelated neuropathies were more frequent (N = 64, 81%), encompassing mainly chemotherapy‐induced (N = 34) and diabetic (N = 15) neuropathies. Five patients (6%) were classified as NURIA: four had mild sensory‐predominant length‐dependent axonal neuropathy, and one had severe, progressive, motor‐predominant axonal neuropathy.Conclusions: In patients with IgA gammopathy, neuropathies have a low prevalence and a wide etiological spectrum. AL amyloidosis and POEMS syndrome are rare but crucial to identify, as disease‐modifying treatments are available. Future studies should help better characterize the rare cases of neuropathy with an uncertain relationship to IgA gammopathy.
- 19 February 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (2) , e70087
Open AccessPrevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy
Background: Neuropathies associated with IgA monoclonal gammopathy are poorly understood, and the interpretation of the presence of such gammopathy in a patient with neuropathy may be challenging.Methods: The neurological and hematological features of all patients newly diagnosed with IgA gammopathy by immunofixation in our center from January 2016 to December 2020 were retrospectively analyzed. Patients with neuropathy were identified through the medical records. The etiology was reviewed by two neurologists and classified into three groups: (i) IgA‐related neuropathies, (ii) IgA‐unrelated neuropathies with an identified alternative etiology, and (iii) neuropathies of uncertain relationship with IgA (NURIA) based on a negative extensive work‐up.Results: Among 585 patients with IgA gammopathy, 79 had neuropathy (14%). Neuropathy was IgA‐related in 10 patients (13%): eight AL amyloidosis and two POEMS. In this group, the core features were neuropathic pain, autonomic dysfunction, fatigue or weight loss, and a lambda light chain. IgA‐unrelated neuropathies were more frequent (N = 64, 81%), encompassing mainly chemotherapy‐induced (N = 34) and diabetic (N = 15) neuropathies. Five patients (6%) were classified as NURIA: four had mild sensory‐predominant length‐dependent axonal neuropathy, and one had severe, progressive, motor‐predominant axonal neuropathy.Conclusions: In patients with IgA gammopathy, neuropathies have a low prevalence and a wide etiological spectrum. AL amyloidosis and POEMS syndrome are rare but crucial to identify, as disease‐modifying treatments are available. Future studies should help better characterize the rare cases of neuropathy with an uncertain relationship to IgA gammopathy.
- 29 May 2024
- Published by SEMES (Sociedad Espanola de Medicina de Urgencias y Emergencias) in Emergencias
- Vol. 35 (3) , 225-+
Acute ataxia induced by nitrous oxide abuse in young adults during the COVID-19 pandemic
- 29 May 2024
- Published by SEMES (Sociedad Espanola de Medicina de Urgencias y Emergencias) in Emergencias
- Vol. 35 (3) , 225-+
Acute ataxia induced by nitrous oxide abuse in young adults during the COVID-19 pandemic
- Open Access
- 21 March 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (7) , e16285
Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy
Background and purpose: Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV‐induced neuropathy (BV‐CN) is a mild distal sensory axonal polyneuropathy. Severe BV‐induced inflammatory neuropathies (BV‐IN) have been described. BV‐IN contribute to lymphoma‐associated morbidity but might be immunotherapy‐responsive. Our primary objective was to evaluate the rate of BV‐IN. Our secondary objectives were to determine risk factors and warning signs.Methods: We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV‐induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV‐IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV‐CN.Results: Among 83 patients, 41 (49%) developed neuropathy: 35 BV‐CN and 6 BV‐IN. Thus, the rate of BV‐IN was 7.2%. Compared to patients with BV‐CN, no predisposing factor was identified. However, patients with BV‐IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV‐IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy.Conclusions: Brentuximab vedotin‐induced neuropathy is an overlooked complication. Based on four easily identifiable “red flags”, we provide an algorithm to help non‐neurologist physicians that care for BV‐treated patients to detect BV‐IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
- 21 March 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (7) , e16285
Open AccessRate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy
Background and purpose: Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV‐induced neuropathy (BV‐CN) is a mild distal sensory axonal polyneuropathy. Severe BV‐induced inflammatory neuropathies (BV‐IN) have been described. BV‐IN contribute to lymphoma‐associated morbidity but might be immunotherapy‐responsive. Our primary objective was to evaluate the rate of BV‐IN. Our secondary objectives were to determine risk factors and warning signs.Methods: We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV‐induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV‐IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV‐CN.Results: Among 83 patients, 41 (49%) developed neuropathy: 35 BV‐CN and 6 BV‐IN. Thus, the rate of BV‐IN was 7.2%. Compared to patients with BV‐CN, no predisposing factor was identified. However, patients with BV‐IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV‐IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy.Conclusions: Brentuximab vedotin‐induced neuropathy is an overlooked complication. Based on four easily identifiable “red flags”, we provide an algorithm to help non‐neurologist physicians that care for BV‐treated patients to detect BV‐IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
- 1 March 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (2) , e200195
Characterizing Acute-Onset Small Fiber Neuropathy
Immune-mediated small fiber neuropathy (SFN) is increasingly recognized. Acute-onset SFN (AOSFN) remains poorly described. Herein, we report a series of AOSFN cases in which immune origins are debatable. We included consecutive patients with probable or definite AOSFN. Diagnosis of SFN was based on the NEURODIAB criteria. Acute onset was considered when the maximum intensity and extension of both symptoms and signs were reached within 28 days. We performed the following investigations: clinical examination, neurophysiologic assessment encompassing a nerve conduction study to rule out large fiber neuropathy, laser-evoked potentials (LEPs), warm detection thresholds (WDTs), electrochemical skin conductance (ESC), epidermal nerve fiber density (ENF), and patient serum reactivity against mouse sciatic nerve teased fibers, mouse dorsal root ganglion (DRG) sections, and cultured DRG. The serum reactivity of healthy subjects (n = 10) and diseased controls (n = 12) was also analyzed. Data on baseline characteristics, biological investigations, and disease course were collected. Twenty patients presenting AOSFN were identified (60% women; median age: 44.2 years [interquartile range: 35.7-56.2]). SFN was definite in 18 patients (90%) and probable in 2 patients. A precipitating event was present in 16 patients (80%). The median duration of the progression phase was 14 days [5-28]. Pain was present in 17 patients (85%). Twelve patients (60%) reported autonomic involvement. The clinical pattern was predominantly non-length-dependent (85%). Diagnosis was confirmed by abnormal LEPs (60%), ENF (55%), WDT (39%), or ESC (31%). CSF analysis was normal in 5 of 5 patients. Antifibroblast growth factor 3 antibodies were positive in 4 of 18 patients (22%) and anticontactin-associated protein-2 antibodies in one patient. In vitro studies showed IgG immunoreactivity against nerve tissue in 14 patients (70%), but not in healthy subjects or diseased controls. Patient serum antibodies bound to unmyelinated fibers, Schwann cells, juxtaparanodes, paranodes, or DRG. Patients' condition improved after a short course of oral corticosteroids (3/3). Thirteen patients (65%) showed partial or complete recovery. Others displayed relapses or a chronic course. AOSFN primarily presents as an acute, non-length-dependent, symmetric painful neuropathy with a variable disease course. An immune-mediated origin has been suggested based on in vitro immunohistochemical studies.
- 1 March 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (2) , e200195
Characterizing Acute-Onset Small Fiber Neuropathy
Immune-mediated small fiber neuropathy (SFN) is increasingly recognized. Acute-onset SFN (AOSFN) remains poorly described. Herein, we report a series of AOSFN cases in which immune origins are debatable. We included consecutive patients with probable or definite AOSFN. Diagnosis of SFN was based on the NEURODIAB criteria. Acute onset was considered when the maximum intensity and extension of both symptoms and signs were reached within 28 days. We performed the following investigations: clinical examination, neurophysiologic assessment encompassing a nerve conduction study to rule out large fiber neuropathy, laser-evoked potentials (LEPs), warm detection thresholds (WDTs), electrochemical skin conductance (ESC), epidermal nerve fiber density (ENF), and patient serum reactivity against mouse sciatic nerve teased fibers, mouse dorsal root ganglion (DRG) sections, and cultured DRG. The serum reactivity of healthy subjects (n = 10) and diseased controls (n = 12) was also analyzed. Data on baseline characteristics, biological investigations, and disease course were collected. Twenty patients presenting AOSFN were identified (60% women; median age: 44.2 years [interquartile range: 35.7-56.2]). SFN was definite in 18 patients (90%) and probable in 2 patients. A precipitating event was present in 16 patients (80%). The median duration of the progression phase was 14 days [5-28]. Pain was present in 17 patients (85%). Twelve patients (60%) reported autonomic involvement. The clinical pattern was predominantly non-length-dependent (85%). Diagnosis was confirmed by abnormal LEPs (60%), ENF (55%), WDT (39%), or ESC (31%). CSF analysis was normal in 5 of 5 patients. Antifibroblast growth factor 3 antibodies were positive in 4 of 18 patients (22%) and anticontactin-associated protein-2 antibodies in one patient. In vitro studies showed IgG immunoreactivity against nerve tissue in 14 patients (70%), but not in healthy subjects or diseased controls. Patient serum antibodies bound to unmyelinated fibers, Schwann cells, juxtaparanodes, paranodes, or DRG. Patients' condition improved after a short course of oral corticosteroids (3/3). Thirteen patients (65%) showed partial or complete recovery. Others displayed relapses or a chronic course. AOSFN primarily presents as an acute, non-length-dependent, symmetric painful neuropathy with a variable disease course. An immune-mediated origin has been suggested based on in vitro immunohistochemical studies.
- 18 August 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 116 (10) , 433-446
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France
- 18 August 2023
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 116 (10) , 433-446
Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France
- Open Access
- 9 June 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (S2) , 456-457
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvement
- 9 June 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (S2) , 456-457
Open AccessTreatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvement